

Attorney Docket No. 5573.210-US
Peschke et al.
Serial No. 09/356,313 Filed July 16, 1999

Attorney Docket No.: 5573.210-US-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
CENTRAL FAX CENTER

FEB 08 2005

In re Application of: Peschke et al.

Confirmation No.: 7669

Application No.: 09/356,313

Group Art Unit: 1653

Filed: July 16, 1999

Examiner: Lukton, David

For: Compounds With Growth Hormone Releasing Properties

AMENDMENT UNDER 37 C.F.R. §1.312

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This amendment is submitted to correct an oversight resulting from an amendment made in Applicant's Amendment/Response mailed November 12, 2004. The Notice of Allowance and Fee(s) Due was mailed January 7, 2005, having a due date of April 7, 2005. The issue fee has not been paid.

Pursuant to 37 C.F.R. §1.121, Applicant submits a complete listing of all of the claims ever presented for this pending application.

Claims numbered 1 and 4 have been amended herein to correct an oversight. No new matter has been entered as a consequence of this amendment.

Applicant believes no fee is necessary to timely file this paper. However, should any petition or fee be required for timely filing of this Amendment, Applicant hereby petitions for such Extension of Time and hereby grants authorization to charge Deposit Account No. 14-1447, in the name of Novo Nordisk Inc., for any such required fee.